Back

PACIFIC-STROKE - Phase 2 Program of AntiCoagulation via Inhibition of FXIa by the oral Compound BAY 2433334 – non-cardioembolic STROKE study.

28 August 2022 (09:14 - 09:26)
Organised by:
Congress Presentation Part of: HOT LINE SESSION 5 Prevention ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Ashkan Shoamanesh

McMaster University, Hamilton (Canada)

11 More presentations in this session

Presentation thumbnail
INVICTUS - Rivaroxaban versus VKA for rheumatic atrial fibrillation.
Professor G. Karthikeyan (New Delhi, IN)
Slides Video
Presentation thumbnail
Discussant review - INVICTUS.
Professor R. Lopes (Durham, US)
Slides Video
Presentation thumbnail
Panel discussion - INVICTUS.
Video
Presentation thumbnail
PACIFIC-AMI - Efficacy and safety of factor XIa inhibitor asundexian on top of dual antiplatelet therapy after acute myocardial infarction .
Professor J. Alexander (Durham, US)
Slides Video
Presentation thumbnail
Discussant review - PACIFIC-AMI.
Doctor M. O'Donoghue (Boston, US)
Slides Video

Access the full session

Session thumbnail
HOT LINE SESSION 5
Video

The Event

Event poster

ESC Congress 2022

28 August 2022 09:14 CET
You may be interested in
thumbnail
Congress Presentation
OCEANIC-AF - Asundexian versus apixaban in patients with atrial fibrillation
1 September 2024
thumbnail
Congress Presentation
Insights from STORM PE: first RCT in aspiration thrombectomy vs. standard of care
21 March 2026
thumbnail
Congress Presentation
Managing stroke patients with indications for both anticoagulant and antiplatelet treatment
31 August 2024
thumbnail
Congress Presentation
BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources